Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

PEITC-containing pharmaceutical composition and application thereof in cancer therapy

A composition and drug technology, which can be used in drug combinations, medical preparations containing active ingredients, antitumor drugs, etc., and can solve problems such as poor prognosis in cancer treatment

Inactive Publication Date: 2017-10-31
JC (WUXI) CO INC
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Once drug resistance emerges, it means poor prognosis for cancer treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PEITC-containing pharmaceutical composition and application thereof in cancer therapy
  • PEITC-containing pharmaceutical composition and application thereof in cancer therapy
  • PEITC-containing pharmaceutical composition and application thereof in cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0178] Preparation of lysate and Western blot analysis

[0179] Different lysates were used to prepare soluble, insoluble, and whole cell lysates. Cells were harvested by washing twice with 1x PBS and used to prepare lysates (soluble). RIPA buffer (10 mM sodium phosphate (pH 7.2), 300 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 1% deoxycholate, 2 mM EDTA) was added to the cells and placed in an ice bath for 30 minutes. The cell suspension was then centrifuged at 18500 xg for 10 min at 4°C and the supernatant was collected unless otherwise mentioned. The precipitate is the insoluble component. The insoluble fraction was dissolved in lysis buffer (65 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2% SDS, 50 mM DTT) containing 2% SDS. Harvested cell pellets were dissolved in 2% SDS lysis buffer to prepare whole cell lysis fractions as described above. The fractions were collected by centrifugation at 18500×g for 10 minutes at 4°C. Then take 30-50μg of the lysate for 4–12% SDS / PAGE electrophores...

Embodiment 1

[0203] The inhibitory effect of PEITC on the proliferation of mutant p53 cells

[0204] 1. PEITC inhibits the proliferation of prostate cancer cells by acting on DU145 mutant p53

[0205] The effect of PEITC on the proliferation of prostate cancer cell line DU145 was studied by WST-1 assay. For this, DU145 cells were treated with different concentrations of PEITC for 72 hours. After that, the corresponding IC50 was calculated by detecting the OD450 value of each group of cells. The results showed that PEITC reduced the proliferation of DU145 cell line (IC 50 s=~8μM)( figure 1 A).

[0206] 2. PEITC acts on breast cancer cells SK-BR-3, AU565 mutant p53 R175 Inhibit its proliferation

[0207] The WST-1 experimental study showed that PEITC can reduce the proliferation of various cells expressing mutant p53. Among them, PEITC expressed p53 R175 Mutant human breast cancer cells SK-BR-3, AU565 and human non-small cell lung cancer HOP92 have the strongest inhibitory effect. I...

Embodiment 2

[0212] PEITC inhibits tumor cell proliferation and induces apoptosis in a mutant p53-dependent manner

[0213] 1. PEITC to p53 R175 or p53 R248 Inhibition of proliferation and induction of apoptosis in breast cancer cell line SK-BR-3 in a dependent manner

[0214] In order to determine whether the effect of PEITC on inhibiting tumor cell proliferation is through making p53 R175 Transformation mediated by altered wild-type p53 activity, WST-1 assay after transfection of p53siRNA shows: p53 R175 SK-BR-3 cells with reduced expression ( figure 2 b) Significantly reduced sensitivity of PEITC to inhibit proliferation, while cells transfected with NS siRNA maintained high sensitivity. However, no significant difference in proliferation was observed in A549 cells in the same experiment ( figure 2 b). The above results indicated that PEITC-induced proliferation inhibition was dependent on mutant p53 protein.

[0215] In order to determine whether PEITC induces tumor cell apopt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of PEITC for preparing a preparation of a composition. The preparation or the composition is used for (a) changing a mutant p53 to restore the wild activity, (b) inhibiting tumor cell proliferation caused by the mutant p53, (c) inducing tumor cell apoptosis of the mutant p53, and / or (d) preventing or treating a disease caused by p53-based mutation. The invention further provides an application of a p53 gene detection reagent, a kit comprising the PEITC and the p53 gene detection reagent and a method for in vitro non-therapeutic inhibition of tumor cells.

Description

technical field [0001] The present invention relates to the field of medicine, more specifically to the pharmaceutical composition containing PEITC and its application in the prevention and treatment of cancer and other diseases caused by p53 mutation. Background technique [0002] 本专利申请是CN200510040865.1、CN200610126892.5、CN200910052231.6、CN201310205609.8、CN201310352414.6、CN201310364101.2和CN201410346419.2以及US8039511B2、US8410170B2、EP06817815.1、CA2630262和JP5308160的后续专利。 [0003] Cancer is a major disease that threatens human health. According to the Global Cancer Report 2014, there were 14 million new cancer cases and 8.2 million deaths worldwide in 2012. Among them, China added 3.07 million cancer patients and caused about 2.2 million deaths, accounting for 21.9% and 26.8% of the global total respectively. [0004] Although remarkable achievements have been made in the treatment and prevention of tumors in recent years due to the progress of epidemiology, further improvement...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/26A61P35/00C12Q1/68G01N33/68G01N33/574A61K36/31
CPCA61K31/26G01N33/574G01N33/68A61K36/31C12Q1/6886C12Q2600/136C12Q2600/156G01N33/57484
Inventor 宗方隆程景才M·阿加沃尔
Owner JC (WUXI) CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com